View Future GrowthKuangli Bio-Tech Holdings 과거 순이익 실적과거 기준 점검 0/6Kuangli Bio-Tech Holdings 의 수입은 연평균 -48.2%의 비율로 감소해 온 반면, Electronic 산업은 연평균 0.4%의 비율로 증가했습니다. 매출은 연평균 12.5%의 비율로 증가해 왔습니다.핵심 정보-48.23%순이익 성장률-40.74%주당순이익(EPS) 성장률Electronic 산업 성장률14.81%매출 성장률12.54%자기자본이익률-34.96%순이익률-55.25%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesReported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).공시 • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city TaiwanNew Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.공시 • Mar 14Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan공시 • Mar 04Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025분석 기사 • Feb 25Kuangli Bio-Tech Holdings Co., Ltd. (TWSE:6431) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedKuangli Bio-Tech Holdings Co., Ltd. ( TWSE:6431 ) shareholders would be excited to see that the share price has had a...Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023)Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m).공시 • Nov 05Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024Reported Earnings • Aug 30Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023)Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.New Risk • Aug 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m).공시 • Aug 17Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m).공시 • May 08+ 1 more updateKuangli Bio-Tech Holdings Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m).분석 기사 • Mar 22Kuangli Bio-Tech Holdings Co., Ltd.'s (TWSE:6431) Shareholders Might Be Looking For ExitWhen close to half the companies in the Electronic industry in Taiwan have price-to-sales ratios (or "P/S") below 1.6x...New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m).New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m).New Risk • Sep 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Apr 07Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022.분석 기사 • Mar 31We're Not Worried About Kuangli Photoelectric Technology's (TPE:6431) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is New 90 Day High Low • Feb 22New 90-day high: NT$34.10The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period.분석 기사 • Feb 03Did Business Growth Power Kuangli Photoelectric Technology's (TPE:6431) Share Price Gain of 248%?When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...Is New 90 Day High Low • Jan 29New 90-day high: NT$31.70The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period.분석 기사 • Dec 09We Think Kuangli Photoelectric Technology (TPE:6431) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Oct 29New 90-day low: NT$26.80The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period.매출 및 비용 세부 내역Kuangli Bio-Tech Holdings가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TWSE:6431 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26353-1951893331 Dec 25377-1931953330 Sep 25387-1931873530 Jun 25425-1821883631 Mar 25429-1731933331 Dec 24381-1731813230 Sep 24333-1481693230 Jun 24285-1501653231 Mar 24300-1141523231 Dec 23293-1041493130 Sep 23325-781403130 Jun 23380-501243231 Mar 23337-661213331 Dec 22342-681253230 Sep 22386-641383030 Jun 22402-641312431 Mar 22418211211831 Dec 2133344871130 Sep 211556947330 Jun 21634451131 Mar 2151-3548031 Dec 2087-4250130 Sep 20333-7962530 Jun 20413-3458631 Mar 20431-2651831 Dec 19425-2847830 Sep 19228-2140730 Jun 19143-1735731 Mar 19110-432631 Dec 18100-1932630 Sep 18100-7434630 Jun 1888-12832631 Mar 1893-15732631 Dec 17107-15933630 Sep 17138-18733730 Jun 17159-19745731 Mar 17183-26550731 Dec 16211-27154830 Sep 16252-29586930 Jun 16310-263831131 Mar 16377-212811231 Dec 15417-208841430 Sep 15429-1115913양질의 수익: 6431 은(는) 현재 수익성이 없습니다.이익 마진 증가: 6431는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6431은 수익성이 없으며 지난 5년 동안 손실이 연평균 48.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 6431의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 6431은 수익성이 없어 지난 해 수익 성장률을 Electronic 업계(-4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6431는 현재 수익성이 없으므로 자본 수익률이 음수(-34.96%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YTech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/02 22:15종가2026/07/02 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kuangli Bio-Tech Holdings Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).
Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).
Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).
Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).
Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).
Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).
공시 • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).
Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).
Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).
Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.
공시 • Mar 14Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
공시 • Mar 04Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025
분석 기사 • Feb 25Kuangli Bio-Tech Holdings Co., Ltd. (TWSE:6431) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedKuangli Bio-Tech Holdings Co., Ltd. ( TWSE:6431 ) shareholders would be excited to see that the share price has had a...
Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023)Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m).
공시 • Nov 05Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024
Reported Earnings • Aug 30Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023)Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
New Risk • Aug 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m).
공시 • Aug 17Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024
New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m).
공시 • May 08+ 1 more updateKuangli Bio-Tech Holdings Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m).
분석 기사 • Mar 22Kuangli Bio-Tech Holdings Co., Ltd.'s (TWSE:6431) Shareholders Might Be Looking For ExitWhen close to half the companies in the Electronic industry in Taiwan have price-to-sales ratios (or "P/S") below 1.6x...
New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m).
New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m).
New Risk • Sep 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Apr 07Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022.
분석 기사 • Mar 31We're Not Worried About Kuangli Photoelectric Technology's (TPE:6431) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Is New 90 Day High Low • Feb 22New 90-day high: NT$34.10The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period.
분석 기사 • Feb 03Did Business Growth Power Kuangli Photoelectric Technology's (TPE:6431) Share Price Gain of 248%?When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Is New 90 Day High Low • Jan 29New 90-day high: NT$31.70The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period.
분석 기사 • Dec 09We Think Kuangli Photoelectric Technology (TPE:6431) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Oct 29New 90-day low: NT$26.80The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period.